PDL BioPharma, Inc. PDLIV
NASDAQ
Recommendation
Dividend Power Score
Day's Range
Latest Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
--
| 08/31/2020 | 06/30/2020 | ||||
|---|---|---|---|---|---|
| Net Income | -- | -57.52% | |||
| Total Depreciation and Amortization | -- | -11.85% | |||
| Total Amortization of Deferred Charges | -- | -26.79% | |||
| Total Other Non-Cash Items | -- | 44.94% | |||
| Change in Net Operating Assets | -- | 67.18% | |||
| Cash from Operations | -- | 31.31% | |||
| Capital Expenditure | -- | -52.69% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -16.01% | |||
| Cash from Investing | -- | -16.48% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | 100.00% | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -4.80% | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | 100.00% | |||
| Cash from Financing | -- | 52.09% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | -- | 53.90% | |||